

20 Ca Calcium	21 Sc Scandium
38 Sr Strontium	39 Y Yttrium

Calcium

Introduction

According to medical anthropologists, calcium intake among Paleolithic people (who ate no dairy products and little meat or fish) averaged 1,500 mg per day.¹ Actual current intakes of hunter-gatherer tribes have been calculated at 2,100-3,000 mg per day.² In contrast, the average daily calcium intake of the adult woman in the United States is 500 mg.³

Several diseases, including osteoporosis, hypertension, and colon cancer have been linked to a drop in calcium intake and to increased dietary phosphorus from grains that has been occurring over the last several centuries.⁴

During the past 20 years, conflicting research in the area of calcium and osteoporosis prevention and treatment has created confusion in the scientific community. This confusion is partly due to the fact that calcium is a threshold nutrient,⁵ which means that above a certain threshold there will be little, if any, improvement in response from increasing the dosage.

There are, however, several areas of clarity that have emerged from the burgeoning amount of research on calcium and bone loss. It now appears the source of calcium and its application in the female life cycle make a substantial difference. There are also indications for the use of calcium in specific types of hypertension, premenstrual syndrome, and prevention of colorectal cancer.

Pharmacokinetics

Absorption of calcium varies with age and the presence or absence of intestinal disease.⁶ Although it has commonly been believed that solubility of a calcium source increases absorbability, absorption studies have not found a predictable linear relationship between solubility and absorption.⁶ Absorption rates of commercially-available calcium supplements vary, with calcium carbonate as low as 22 percent⁷ and calcium citrate malate (CCM) as high as 42 percent.⁸ Studies looking at actual absorption of calcium supplements vary significantly based on the intra-individual differences in absorption capacity, including hydrochloric acid production.

Calcium research in the area of osteoporosis is difficult due to the complex nature of maintaining calcium balance. Twenty-five percent of the variance in calcium balance is a result of absorption differences, and absorption in menopausal women can vary as much as 61 percent. In some calcium trials, malabsorption of calcium was so common that 40 percent of women in the trials could not absorb enough calcium to stay in calcium balance even though they were ingesting 800 mg daily.⁹

Mechanisms of Action

Calcium has life-sustaining functions in all living cells, acting as a second messenger in transmitting signals between cellular plasma membranes and intracellular signal receptors. In the extracellular environment calcium is essential in promoting blood clotting and the production of cellular adhesion molecules. Recent evidence shows cell membranes in the kidney, parathyroid gland, and brain have specific receptors for calcium that initiate intracellular signals.¹⁰

In the kidney, calcium lowers dopaminergic activity, resulting in increased urinary volume and loss of sodium, a possible mechanism for calcium's blood pressure lowering effect.¹¹ Calcium supplementation also lowers levels of osteocalcin and parathormone (PTH), as well as 1,25-dihydroxy vitamin D. Both PTH and 1,25-dihydroxy vitamin D have hypertensive effects via increases in vascular tone.¹² Although the mechanism is not clear, calcium supplementation in subjects with essential hypertension appears to have an insulin-normalizing and insulin-sensitizing effect at levels of 2,000 mg daily.¹³ Calcium also promotes normal histology of the colonic mucosa. It forms insoluble complexes with fatty acids and bile acids, preventing colonic hyperplasia induced by bile acids and dietary fats.¹⁴ Calcium also appears to have direct effects on normal proliferation of colonic epithelium.¹⁵

Calcium, physical exercise, and gonadal hormones are the most important factors influencing bone mass and density.¹⁶ By decreasing circulating levels of 1,25-dihydroxy vitamin D and PTH, calcium alters the remodeling rate of bone tissue by increasing osteoblast activity, thereby increasing bone density.¹⁷

Clinical Indications

Premenstrual Syndrome

At midcycle, levels of serum ionized calcium in menstruating women drop significantly with a simultaneous elevation of estradiol.¹⁸ Women with premenstrual syndrome (PMS), however, have significantly lower levels of serum ionized calcium and 25-hydroxy vitamin D and higher levels of PTH at midcycle than age-matched women who are symptom free.¹⁹ In women with PMS there is evidence that midcycle elevations of PTH and fluctuations of serum calcium and vitamin D occur more significantly than at other times in the cycle.¹⁸

A randomized, placebo-controlled, double-blind study of calcium in women with PMS showed a significant relationship between PMS symptoms and calcium intake. Supplementation of 1,200 mg/day calcium in 466 women with moderate-to-severe recurrent premenstrual syndrome resulted in a 48-percent reduction of PMS symptoms after three months of use ($p < 0.001$).¹⁸ The mechanism for calcium's benefit for PMS is not known, although the vasoactive effects of low serum calcium and elevated PTH and 1,25-dihydroxy vitamin D may play a role.

Hypertension

The effect of calcium in hypertension is seen most clearly in those with low calcium intakes, indicating a role for calcium supplementation in treating hypertension, both in children and adults who have low dietary calcium levels.^{20,21} Dietary calcium and magnesium were found to be independently associated with hypertension risk in 58,218 females in the Nurses' Health Study.²² Those with dietary intakes of less than 700 mg calcium per day were at higher risk for hypertension than those with intakes higher than 700 mg per day.^{23,24} Although a recent meta-analysis of calcium and hypertension revealed only small changes in blood pressure (-1.44 mm Hg systolic and -0.84 mm Hg),²⁵ studies using calcium along with vitamin D have resulted in significant results. In elderly women, 1,200 mg calcium plus 800 IU vitamin D resulted in a nine-percent decrease in systolic blood pressure.²⁶

It appears that baseline dietary calcium levels are also a significant factor in pregnant women and their risk for hypertension and preeclampsia. Studies with lower calcium-intake populations demonstrated significant effects on risk for hypertension.²⁷ A supplemental dose of 1,800 mg calcium carbonate, taken from 24 weeks to term, reduced the relative risk of preeclampsia and risk for preterm birth – each by more than 50 percent.²⁸

Colorectal Cancer

Low dietary intakes of both calcium and vitamin D have been associated with increased risk for colorectal cancers. Conversely, those with higher dietary intakes are at lower risk.^{29,30} A three-year intervention trial found 1,600 mg elemental calcium (4.0 grams calcium carbonate) daily was effective in reducing both adenoma growth and rectal epithelial hyperplasia in those who were cancer free, and decreasing the occurrence of new adenomas in those with a history of polyps.³¹ A similar intervention trial with 1,200 mg elemental calcium (3 grams calcium carbonate) daily lead to a significantly lower risk for recurrence of colorectal adenoma.³²

Kidney Stones

Calcium restriction has been an accepted therapy for the prevention of recurrent nephrolithiasis. Epidemiological studies, however, have found an inverse relationship between dietary calcium levels and kidney stone formation.^{33,34} Although increased urinary calcium is a risk factor for kidney stone formation,³⁵ calcium citrate or calcium citrate malate (CCM) supplementation actually reduces risk of oxalate stone formation. Trials with 800 mg elemental calcium as citrate increased urinary citrate and reduced calcium oxalate production, decreasing risk for oxalate stone formation.³⁶

Calcium citrate malate, in doses of 300 mg elemental calcium, inhibits the absorption of oxalate from the gut and consequently decreases urinary oxalate levels.³⁷ When 600 mg CCM was given to patients with idiopathic hypercalciuria, the urine pH and urine citrate levels rose; both urine alkalinity and elevated citric acid levels have protective effects against stone formation.³⁸

Age-related Osteoporosis

Emphasis on building peak bone mass is the most crucial step in osteoporosis prevention. More than 90 percent of bone mass is acquired before age 20 and acquisition of peak bone mass ends by age 30.¹⁷ If peak bone density in young adults reaches one standard deviation above normal levels for that age group, a 15-percent loss of total bone mass during menopause will not result in negative consequences. Studies with adolescents given 500 mg calcium citrate malate per day in addition to approximately 1,000 mg calcium from dietary sources resulted in additional bone growth equal to 1.3 percent of the total skeleton per year.³⁹ If this growth was sustained through adulthood, the total gain would ensure protection against menopausal bone loss. Further studies in adolescents have repeated these findings and support the need for a re-evaluation of the National Institutes of Health (NIH) guidelines for calcium intake in this age group. Optimal gains in bone mass were achieved with total calcium intakes of an average of 1,600 mg daily.⁴⁰

During the first 5-7 years of menopause, bone loss is under hormonal control and researchers in the field have agreed calcium supplementation alone is not able to alter the average of 15 percent bone loss that occurs, nor is calcium alone able to reduce risk of spinal fracture.¹⁷ However, in three separate meta-analyses of calcium's effect in reducing bone loss prior to and after menopause in women and in men over 40, calcium had a significant effect in preventing bone loss. In postmenopausal populations calcium was effective in preventing the one-percent bone loss per year that occurs as the average postmenopausal bone-mass decline.⁴¹⁻⁴³

Relative risk of fracture is the most sensitive and accurate way to assess the efficacy of treatments for osteoporosis. Studies with CCM in combination with vitamin D (500 mg CCM and 700 IU vitamin D) in menopausal women reduced non-vertebral fracture risk by 50 percent,

equivalent to hormone replacement therapy.⁴⁴ Another large trial using a calcium triphosphate and vitamin D3 combination protocol has replicated this research.⁴⁵

Glucocorticoid-induced Osteoporosis

Glucocorticoids have an immediate effect on bone metabolism by impeding formation and accelerating resorption of bone, inhibiting calcium absorption, suppressing circulating estrogen, and increasing urinary calcium levels. Glucocorticoid-induced osteoporosis is the most devastating side effect of long-term glucocorticoid therapy and the second most common form of osteoporosis seen in subspecialty clinics.⁴⁶ It is recommended that those receiving long-term (more than six months) treatment with glucocorticoids at doses over 7.5 mg/day be monitored every 6-12 months for bone loss.⁴⁷ Studies support the use of calcium and vitamin D in these patients as a means to maintain and increase bone density (in some trials). Dosages of 800-1,000 mg calcium carbonate and 250-500 IU vitamin D daily have stabilized lumbar and hip bone density in those on low-dose prednisone (11-15 mg).^{48,49}

Drug-Nutrient Interactions

Inhibition of Drug Absorption

Calcium interferes with absorption of some drugs, including bisphosphonates for osteoporosis, quinilone antibiotics (ciprofloxacin, gatifloxacin, etc.), and tetracycline.⁵⁰ Calcium carbonate was found to decrease absorption of levothyroxine, while increasing serum thyrotropin levels.⁵⁰ Calcium supplements should be taken at a different time of day than these medications.

Inhibition of Calcium Absorption

Absorption of calcium can be inhibited by H₂ blockers (cimetidine, ranitidine, etc.), proton pump inhibitors, inositol hexaphosphate, sodium alginate, and oxalate- and phytic-acid rich foods.⁵⁰ Calcium may also be depleted by the use of thiazide diuretics.⁵¹

Enhancement of Calcium Absorption

Absorption of calcium is enhanced by consumption of vitamin D, vitamin D analogs (calcitriol, alfacalcidol), and fructooligosaccharides.⁵⁰

Side Effects and Toxicity

Dosages up to 2,500 mg per day are considered safe in healthy adults.² People with idiopathic hypercalciuria, hyperparathyroidism, vitamin D intoxication, milk-alkali syndrome, and sarcoidosis may need special consideration.

Dosage

Dosages for calcium vary with individual age, gender, and condition. Federal guidelines for calcium intake are sex- and age-specific and vary from 1,000-1,300 mg per day.¹⁷ As indicated by research in adolescent women, higher doses, in the range of 1,500 mg daily, may be a better recommendation.⁴⁰

References

1. Eaton SB, Konner M. Paleolithic nutrition: a consideration of its nature and current implications. *New Engl J Med* 1985;312:283-289.
2. Heaney RP. Non-pharmacologic prevention of osteoporosis. In: Meunier PJ, ed. *Osteoporosis: Diagnosis and Management*. St. Louis, MO: Mosby; 1998:162-163.
3. Carroll MD, Abraham S, Dresser CM. Dietary Intake Source Data US, 1976-1980. *Vital Health Stat* 1983;11:1-483.
4. Heaney RJ, Barger-Lux MJ. ADSA Foundation Lecture. Low calcium intake: the culprit in many chronic diseases. *J Dairy Sci* 1994;77:1155-1160.
5. Matkovic V. Calcium balance during human growth: evidence for threshold behavior. *Am J Clin Nutr* 1992;55:992-996.
6. Heaney RP, Recker R, Weaver CM. Absorbability of calcium sources: the limited role of solubility. *Calcif Tissue Int* 1990;46:300-304.
7. Recker RR, Bammi A, Barger-Lux MJ, et al. Calcium absorbability from milk products, imitation milk, and calcium carbonate. *Am J Clin Nutr* 1998;47:93-95.
8. Andon M, Peacock M, Kanerva RL. Supplemental trials with calcium citrate malate: evidence in favor of increasing the calcium RDA during childhood and adolescence. *J Nutr* 1994;124:1412S-1417S.
9. Heaney R, Recker R. Distribution of calcium absorption in middle-aged women. *Am J Clin Nutr* 1986;43:299-305.
10. Brown EM, Gamba G, Riccardi D, et al. Cloning and characterization of an extracellular Ca²⁺ sensing receptor from bovine parathyroid. *Nature* 1993;366:575-580.
11. Dazai Y, Iwata T, Hiwada K. Augmentation of the renal tubular dopaminergic activity by oral calcium supplementation in patients with essential hypertension. *Am J Hypertens* 1993;6:933-937.
12. Sowers JR, Zemel MB, Zemel PC, et al. Calcium metabolism and dietary calcium in salt-sensitive hypertension. *Am J Hypertens* 1991;4:557-563.
13. Sanchez M, de la Sierra A, Coca A, et al. Oral calcium supplementation reduces intraplatelet free calcium concentration and insulin resistance in essential hypertensive patients. *Hypertension* 1997;29:531-536.
14. Garay CA, Engstrom PF. Chemoprevention of colorectal cancer: dietary and pharmacologic approaches. *Oncology (Huntingt)* 1999;13:89-97.
15. Bostick RM. Human studies of calcium supplementation and colorectal epithelial cell proliferation. *Cancer Epidemiol Biomarkers Prev* 1997;6:971-980.
16. Heaney RP. Nutritional factors in osteoporosis. *Annu Rev Nutr* 1993;13:287-316.
17. Power ML, Heaney RP, Kalwkar JH. The role of calcium in health and disease. *Am J Obstet Gynecol* 1999;181:1560-1569.
18. Thys-Jacobs S, Alvir J. Calcium regulating hormones across the menstrual cycle: evidence of a secondary hyperparathyroidism in women with PMS. *J Clin Endocrinol Metab* 1995;80:2227-2232.
19. Penland JG, Johnson PE. Dietary calcium and manganese effects on menstrual cycle symptoms. *Am J Obstet Gynecol* 1993;168:1417-1423.

20. Repke JT, Robinson JN. The prevention and management of pre-eclampsia and eclampsia. *Int J Gynaecol Obstet* 1998;62:1-9.
21. Bukoski RD, Ishibahi K, Bian K. Vascular actions of the calcium-regulating hormones. *Semin Nephrol* 1995;15:536-549.
22. Witterman JCM, Willett WC, Stampfer MJ, et al. A prospective study of nutritional factors and hypertension among U.S. women. *Circulation* 1989;80:1320-1327.
23. McCarron DA, Morris CD, Young E, et al. Dietary calcium and blood pressure: modifying factors in specific populations. *Am J Clin Nutr* 1991;54:215S-219S.
24. Barger-Lux MJ, Heaney R. The role of calcium intake in preventing bone fragility, hypertension, and certain cancers. *J Nutr* 1994;124:1406S-1411S.
25. Griffith LE, Guyatt GH, Cook RJ, et al. The influence of dietary and nondietary calcium supplementation on blood pressure: an updated metaanalysis of randomized controlled trials. *Am J Hypertens* 1999;12:84-92.
26. Pfeifer M, Bergerow B, Minne HW, et al. Effects of a short-term vitamin D₃ and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. *J Clin Endocrinol Metab* 2001;86:1633-1637.
27. Bucher HC, Guyatt GH, Cook RJ, et al. Effect of calcium supplementation on pregnancy-induced hypertension and preeclampsia: a meta-analysis of randomized controlled trials. *JAMA* 1996;275:1113-1117.
28. Crowther CA, Hiller JE, Pridmore B, et al. Calcium supplementation in nulliparous women for the prevention of pregnancy-induced hypertension, preeclampsia and preterm birth: an Australian randomized trial. FRACOG and the ACT Study Group. *Aust N Z J Obstet Gynaecol* 1999;39:12-18.
29. Garland CF, Garland FC, Gorham ED. Can colon cancer incidence and death rates be reduced with calcium and vitamin D? *Am J Clin Nutr* 1991;54:193S-201S.
30. Kampman E, Slattery ML, Caan B, et al. Calcium, vitamin D, sunshine exposure, dairy products and colon cancer risk. *Cancer Causes Control* 2000;11:459-466.
31. Hofstad B, Almendigen K, Vatn M, et al. Growth and recurrence of colorectal polyps: a double-blind 3-year intervention with calcium and antioxidants. *Digestion* 1998;59:148-156.
32. Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. *N Engl J Med* 1999;340:101-107.
33. Curhan GC, Willett WC, Rimm EB, et al. A prospective study of dietary calcium and other nutrients and the risk of symptomatic kidney stones. *N Engl J Med* 1993;328:880-882.
34. Curhan GC, Willett WC, Speizer FE, et al. Comparison of dietary calcium and supplemental calcium and other nutrients as factors affecting the risk of kidney stones in women. *Ann Intern Med* 1997;126:497-504.
35. Cappuio FP, Kalaitzidis R, Duneclift S, et al. Unraveling the links between calcium excretion, salt intake, hypertension, kidney stones, and bone metabolism. *J Nephrol* 2000;12:169-177.
36. Harvey JA, Zobitz MM, Pak CY. Calcium citrate: reduced propensity for the crystallization of calcium oxalate in urine resulting from induced hypercalciuria of calcium supplementation. *J Clin Endocrinol Metab* 1985;61:1223-1225.
37. Liebman M, Chai W. Effect of dietary calcium on urinary oxalate excretion after oxalate loads. *Am J Clin Nutr* 1997;65:1453-1459.
38. Coe FL, Parks JH, Webb DR. Stone-forming potential of milk or calcium-fortified orange juice in idiopathic hypercalciuric adults. *Kidney Int* 1992;41:139-142.
39. Lloyd T, Andon MB, Rollis N. Calcium supplementation and bone mineral density in adolescent girls. *JAMA* 1993;270:841-844.
40. Patrick L. Comparative absorption of calcium sources and calcium citrate malate for the prevention of osteoporosis. *Altern Med Rev* 1999;4:74-85.

41. Heaney R. Nutrition and risk for osteoporosis: In: Marcus R, Feldman D, Kelsey J, eds. *Osteoporosis*. San Diego, CA: Academic Press Inc.; 1996;498-499.
42. Cumming RG. Calcium intake and bone mass: a quantitative review of the evidence. *Calc Tissue Int* 1990;47:194-201.
43. Welten DC, Kemper HC, Post GB, et al. A meta-analysis of the effect of calcium on bone mass in young and middle aged females and males. *J Nutr* 1995;125:2802-2813.
44. Dawson-Hughes B, Harris S, Krall E, et al. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997;337:670-676.
45. Chapuy MC, Arlot M, Dunboeuf F. Vitamin D3 and calcium to prevent hip fractures in elderly women. *N Engl J Med* 1997;327:1637-1642.
46. Dempster D, Lindsay R. Pathogenesis of osteoporosis. *Lancet* 1993;341:797-801.
47. No authors listed. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee of Glucocorticoid-Induced Osteoporosis. *Arthritis Rheum* 2001;44:1496-1503.
48. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low dose corticosteroids in patients with rheumatoid arthritis: a randomized, double-blind, placebo controlled trial. *Ann Intern Med* 1996;125:961-986.
49. Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis. *N Engl J Med* 1998;339:292-299.
50. Hendler SS, Rorvik D. *PDR for Nutritional Supplements*, 1st ed. Des Moines, IA: Medical Economics – Thompson Healthcare; 2001.
51. Pelton R, LaValle JB, Hawkins EB, Krinsky DL. *Drug-induced Nutrient Depletion Handbook*, 2nd ed. Hudson, OH: Lexi-comp, Inc; 2001.